Merck KGaA Reports Strong Q2, Raises 2024 Guidance

Darmstadt, July 26, 2024: Merck KGaA has reported a robust second quarter for 2024. The company achieved net sales of EUR 5.352 billion, an EBITDA pre1 of EUR 1.509 billion, and an EPS pre1 of EUR 2.20. Consequently, Merck KGaA has raised its forecast for the entire fiscal year 2024.

The company now expects net sales to be around EUR 20.7 - 22.1 billion, a slight increase from the previous projection. EBITDA pre1 is anticipated to grow to approximately EUR 5.8 – 6.4 billion, and EPS pre1 is projected to be around EUR 8.20 – 9.30. These adjustments reflect the strong performance in the Healthcare and Electronics sectors.

The Q2 results were driven by Healthcare's strong operating performance, which offset a mid-double-digit million euro provision associated with xevinapant. Meanwhile, the Life Science sector's performance met expectations.